Home > Insider Trading > Filing (0001127602-11-016669)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
874663	Alkermes Inc	ALKS	Pharmaceutical Preparations (2834)	232472830

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1235595	L Kathryn Biberstein	852 Winter St. Waltham MA 02451	Svp, General Counsel	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2011-05-13	8,800	$7.69	41,232	No	4	M	Direct
Common Stock	Disposition	2011-05-13	8,800	$18.00	32,432	No	4	S	Direct
Common Stock	Acquisiton	2011-05-16	52,012	$7.69	84,444	No	4	M	Direct
Common Stock	Disposition	2011-05-16	52,012	$18.01	32,432	No	4	S	Direct
Common Stock	Acquisiton	2011-05-16	64,188	$7.69	96,620	No	4	M	Direct
Common Stock	Disposition	2011-05-16	64,188	$18.01	32,432	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non Qualified Stock Option (Right to Buy)	Disposition	2011-05-13	8,800	$0.00	8,800	$7.69
Common Stock	Incentive Stock Option (Right to Buy)	Disposition	2011-05-16	52,012	$0.00	52,012	$7.69
Common Stock	Non Qualified Stock Option (Right to Buy)	Disposition	2011-05-16	64,188	$0.00	64,188	$7.69

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
164,188	2004-02-03	2013-02-03	No	4	M	Direct
0	2004-02-03	2013-02-03	No	4	M	Direct
100,000	2004-02-03	2013-02-03	No	4	M	Direct

Footnotes

This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The range of sale prices was $18.00 to $18.02. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The range of sale prices was $18.00 to $18.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The option becomes exercisable in equal annual installments over a four year period, at the rate of 25% per year commencing one year after the grant date.